Latest Breaking News On - Department of investigational cancer therapies phase - Page 1 : comparemela.com

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes Overall response of 33.3% across all tumor types and.

United statesTimothya yapMaria koehlerLloydm segalRepare therapeutics incHead of clinical developmentExchange commissionInternational conference on molecularCompany quarterly report on formUniversity of texas md anderson cancer centerCompany nasdaqCompany virtual webcast eventDepartment of investigational cancer therapies phaseTherapeutics discovery divisionCompany annual report on formRepare therapeutics

Repare Therapeutics (RPTX) Reports Positive Initial Data from Phase 1 MYTHIC Clinical Trial

Repare Therapeutics (RPTX) Reports Positive Initial Data from Phase 1 MYTHIC Clinical Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLloydm segalMaria koehlerTimothya yapDepartment of investigational cancer therapies phaseTherapeutics discovery divisionRepare therapeutics incInternational conference on molecularUniversity of texas md anderson cancer centerHead of clinical developmentRepare therapeuticsMolecular targetsCancer therapeuticsChief executive officerInvestigational cancer therapiesVice president